Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageDanaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics). United by the DANAHER BUSINESS SYSTEM (“DBS”), our businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily through a direct sales model and to a geographically diverse customer base.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $2.47BThe company’s own SEC segment disclosure.
- Diagnostics$1.13B46%
- Life Sciences$759.0M31%
- Biotechnology$583.0M24%
Danaher Corporation (DHR) reported revenue of $6.26B in Q2 2026 (quarter ended June 26, 2026), up 5.5% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $870M (14% of revenue). For the full year FY2025, revenue was $24.6B (+2.9% year on year) and net income $3.61B. Its largest segment in 2026-Q2 was Diagnostics at $1.13B, 46% of the disclosed total, just ahead of Life Sciences at 31%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #23 of 29 by Smart Score